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TO THE EDITOR
Cutaneous malignant melanoma (CMM)
is one of the most common cancers in
the Western world, with a rapidly
increasing incidence. Clinically, CMM
is a highly heterogeneous disease that is
currently staged according to the Amer-
ican Joint Committee on Cancer (AJCC)
system, which is based on the thickness
of the tumor, ulceration status, mitotic
rate, and node involvement (Balch
et al., 2009). Molecular testing has
explained some of this heterogeneity.
On the basis of the frequent BRAF
mutations in CMM (Davies et al.,
2002), and their virtually mutually
exclusive occurrence with NRAS muta-
tions, tumors are today molecularly
subgrouped by BRAF and NRAS
mutation status. This mutation status is
believed to correlate with histological
and clinical tumor phenotypes (Curtin
et al., 2005). Molecular classification of
CMM based on gene expression profiles
was recently described, identifying four
distinct phenotypes (proliferative, high-
immune, normal-like, and pigmenta-
tion) independent of BRAF or NRAS
mutations and associated with patient
outcome independent of other progno-
stic factors (Jonsson et al., 2010; Harbst
et al., 2012).
Familial CMM accounts for B10% of
all CMM cases (Hayward, 2003). The
most common high-penetrance mela-
noma susceptibility gene is CDKN2A,
located at chromosome band 9p21.
Distinct CDKN2A founder mutations
exist, including the Swedish p.R112_
L113insR and the Dutch c.225-
243del19 mutations (Hayward, 2003).
Additional germline mutations in CDK4,
MITF, TERT, and POT1 have also been
described in a few CMM families
(Yokoyama et al., 2011; Horn et al.,
2013; Puntervoll et al., 2014; Robles-
Espinoza et al., 2014).
In this study, we aimed to determine
whether primary melanomas from
CDKN2A mutation carriers exhibit a
distinct gene expression signature. To
this end we collected formalin-fixed
paraffin-embedded primary CMMs from
five centers in Europe and Australia,
including 237 sporadic cases and 43
tumors from CDKN2A carriers, with the
addition of 6 normal skin and 11 nevus
specimens (n¼297 in total) (Table 1).
Among CDKN2A carriers, 31 out of 43
CDKN2A carriers harbored the Swedish
founder mutation p.R112_L113insR and
five harbored the Dutch founder muta-
tion c.225-243del19. The sporadic
CMMs consisted of samples from a
consecutive Swedish cohort (thickness
40.8 mm to ensure sufficient DNA and
RNA, n¼ 225) collected at the Depart-
ment of Pathology, Lund University, as
previously described (Harbst et al.,
2012), and 12 sporadic cases from
Brisbane, Leiden, and Stockholm. From
the 297 samples RNA and DNA were
extracted, and global gene expression
data were obtained using the WG-DASL
technique as described (Harbst et al.,
2012). The Sequenom Oncocarta panel
v1 was used to determine oncogene
mutation status in a subset of 166
tumors as described (Harbst et al.,
2012). p16 nuclear and PTEN immuno-
histochemical (IHC) analysis was
performed on 13 CDKN2A and 152
sporadic cases, respectively (Supple-
mentary Information online). The study
was approved by the Ethics Review
Boards of each participating center
according to the Declaration of Helsinki
guidelines.
As expected, age at diagnosis
(Goldstein et al., 2007) and Clark’s
level of invasion and Breslow thickness
(borderline significant) differed between
the CDKN2A and sporadic cohorts
(Table 1). Moreover, 54% and 9% of
CDKN2A carriers had mutations in
BRAF and NRAS, respectively, com-
pared with 29% and 18% in sporadic
cases (P¼0.03). However, this differ-
ence in mutation frequency between the
groups was lost when adjusting for
thickness and age at onset, representing
features previously associated with
BRAF mutation (Scolyer et al., 2011).
Notably, these results are consistent
with a study by Zebary et al. (2014)
reporting no difference in BRAF
and NRAS mutation frequencies bet-
ween CDKN2A carriers and matched
sporadic cases.
To investigate whether CDKN2A
mutation carriers displayed gene expres-
sion patterns different from sporadic
CMM, we applied principal component
analysis (PCA) to the expression data
from the 297-sample cohort, finding that
CDKN2A carriers were firmly intermin-
gled with sporadic cases (Figure 1a). In
addition, PCA showed that the main
variation in gene expression in CMM
was related to specific clinicopathologi-
cal factors (tumor thickness and histol-
ogy) and gene expression phenotypes,
whereas CDKN2A mutation status con-
tributed little to the overall variation
(Supplementary Figure 1 online). To
further investigate the molecular land-
scape of melanomas from CDKN2A
carriers, we classified the 280 familial
and sporadic tumors according to our
reported gene expression pheno-
types (Jonsson et al., 2010; Harbst
et al., 2012). Here, we found overall
similar frequencies of gene expression
phenotypes in the CDKN2A and spo-
radic cohorts, but with a slightly higher
frequency of normal-like melanomas in
the CDKN2A cohort (P¼ 0.02, Table 1,
Figure 1b). However, after adjustment
for thickness and age at onset, this
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statistical difference was lost. Finally,
we searched for differentially expressed
genes between CDKN2A carriers and
sporadic CMMs. On the basis of signifi-
cance analysis of microarrays (SAM)
only seven genes showed a significant
difference (q-value¼ 0) (Figure 1c).
Notably, the maximum fold change of
these genes was o1.4, suggesting very
subtle changes not inconsistent with
random observations. Moreover, to
determine the validity of the differences
in these seven genes, an independent
CMM cohort including CDKN2A muta-
tion carriers needs to be analyzed.
Although gene expression differences
stratified on somatic CDKN2A mutation
status have been observed in other
tumor types (Jardin et al., 2010), our
gene expression analyses suggest that
CMMs from CDKN2A germline muta-
tion carriers do not constitute a distinct
gene expression subtype and that only
subtle, if any, gene expression diffe-
rences characterize melanomas from
CDKN2A carriers.
Results from the gene expression ana-
lyses are further corroborated by p16
nuclear IHC analysis of 152 sporadic
cases from our cohort, wherein 125
demonstrated a complete loss of p16
nuclear staining (Table 1 and Figure 1d).
This suggests that loss of nuclear p16
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Figure 1. Gene expression landscape of melanomas from CDKN2A mutation carriers compared with sporadic melanomas. (a) Principal component
analysis (PCA) 3D-plot highlighting the gene expression profile similarities between primary melanomas from CDKN2A carriers (black dots) and sporadic
cases (yellow dots). mRNA levels for 7,752 genes in 297 samples, including 17 normal skin and nevi (light-gray dots), are included in the analysis. (b) Classification
of primary melanomas in the four gene expression phenotypes based on 270 genes described by Harbst et al. (2012). Melanoma tumors (n¼280)
are ordered according to gene expression phenotype, CDKN2A mutation status, and centroid correlation coefficient. Melanomas from CDKN2A mutation
carriers (n¼ 43) are denoted by black bars. (c) Genes differentially expressed between melanomas from CDKN2A carriers and sporadic cases. Fold change is
unlogged and is relative to the CDKN2A carriers; that is, STAT4 is downregulated in melanomas from carriers as compared with sporadic cases. (d) Comparison
of molecular and clinical features in different subsets of melanomas.
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protein is an early event in melano-
magenesis and may partly explain why
melanomas from CDKN2A carriers are
molecularly almost indistinguishable
from sporadic cases. Moreover, in mel-
anoma tumors the MAPK and the PI3K
pathways are commonly altered (Hodis
et al., 2012). PTEN, a regulator of
the PI3K pathway, is a major tumor
suppressor in melanoma, and PTEN
gene alterations are commonly found
in CMM. However, we found no
difference in PTEN protein expression
by IHC between CDKN2A carriers and
sporadic cases (P¼ 0.08, Table 1 and
Figure 1d), indicating that deficiencies
of the PI3K pathway occur in both
sporadic and familial melanoma.
In conclusion, this is the only study,
to our knowledge, investigating gen-
ome-wide molecular changes in primary
melanomas from CDKN2A mutation
carriers. Although larger numbers of
familial tumors could potentially iden-
tify additional subtle molecular altera-
tions between familial and sporadic
cases, our results strongly suggest that
melanomas from CDKN2A mutation
carriers are not associated with a
distinct gene expression signature and
that overall they have similar mole-
cular characteristics to sporadic
melanomas.
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Table 1. Clinicopathological and molecular features of sporadic melanomas





cases (n¼237)1 P-value2 P-value3
Gender
Male 22 (55) 113 (51) 0.63 —
Female 18 (45) 109 (49)
Median thickness (mm) 1.97 (0.4–14.2) 3.05 (0.6–25) 0.06 0.27
Site4
Head/neck 9 (24) 30 (14) 0.02 0.11
Trunk 16 (39) 127 (60)
Extremities 14 (34) 37 (17)
Other 1 (2) 18 (8)
Clark
II 10 (26) 6 (3) 0.0002 0.0003
III 13 (33) 84 (42)
IV 13 (33) 97 (48)
V 3 (8) 15 (7)
Histology5
SSM 25 (74) 107 (49) 0.08 —
NM 9 (26) 79 (36)
Other — 33 (15)
Age at diagnosis 47 (26–85) 64 (14–101) o0.001 o0.001
Mutation status
BRAF mutation 18 (54) 38 (29) 0.03 0.06
NRAS mutation 3 (9) 24 (18)
Wild type 13 (37) 70 (53)
Gene expression phenotype
High-immune 4 (9) 64 (27) 0.02 0.13
Normal-like 18 (41) 59 (25)
Pigmentation 15 (36) 87 (37)
Proliferative 3 (7) 22 (9)
Unclassified 3 (7) 5 (2)
Nuclear p16 IHC
Absent 13 (100) 125 (82) 0.99 —
Present 0 (0) 27 (18)
PTEN IHC
Absent 6 (43) 36 (24) 0.08 —
Present 7 (57) 116 (76)
Abbreviations: IHC, immunohistochemistry; NM, nodular melanoma; SSM, superficial spreading
melanoma.
1Number of cases with percentage in brackets, except range in brackets for thickness and age.
2Univariate logistic regression.
3Multivariate logistic regression. All P-values adjusted for thickness and age at diagnosis.
4Other sites were excluded in analysis because of only one case in the CDKN2A cohort.
5For histology only SSM and NM are included in P-value calculation.
P-valueso0.05 are indicated as bold.
J Staaf et al.
Primary Melanoma Tumors from CDKN2A Mutation Carriers
3002 Journal of Investigative Dermatology (2014), Volume 134
4Department of Oncology-Pathology,
Karolinska Institute, Stockholm, Sweden;
5QIMR Berghofer Medical Research Institute,
Brisbane, Australia and 6Department of
Dermatology, LUMC, Leiden, The Netherlands
E-mail: goran_b.jonsson@med.lu.se
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Balch CM, Gershenwald JE, Soong SJ et al. (2009)
Final version of 2009 AJCC melanoma staging
and classification. J Clin Oncol 27:6199–206
Curtin JA, Fridlyand J, Kageshita T et al. (2005)
Distinct sets of genetic alterations in mela-
noma. N Engl J Med 353:2135–47
Davies H, Bignell GR, Cox C et al. (2002) Muta-
tions of the BRAF gene in human cancer.
Nature 417:949–54
Goldstein AM, Chan M, Harland M et al. (2007)
Features associated with germline CDKN2A
mutations: a GenoMEL study of melanoma-
prone families from three continents. J Med
Genet 44:99–106
Harbst K, Staaf J, Lauss M et al. (2012) Molecular
profiling reveals low- and high-grade forms of
primary melanoma. Clin Cancer Res 18:
4026–36
Hayward NK (2003) Genetics of melanoma pre-
disposition. Oncogene 22:3053–62
Hodis E, Watson IR, Kryukov GV et al. (2012) A
landscape of driver mutations in melanoma.
Cell 150:251–63
Horn S, Figl A, Rachakonda PS et al. (2013) TERT
promoter mutations in familial and sporadic
melanoma. Science 339:959–61
Jardin F, Jais JP, Molina TJ et al. (2010) Diffuse
large B-cell lymphomas with CDKN2A
deletion have a distinct gene expression
signature and a poor prognosis under
R-CHOP treatment: a GELA study. Blood
116:1092–104
Jonsson G, Busch C, Knappskog S et al. (2010)
Gene expression profiling-based identification
of molecular subtypes in stage IV melanomas
with different clinical outcome. Clin Cancer
Res 16:3356–67
Puntervoll HE, Yang XR, Vetti HH et al. (2014)
Melanoma prone families with CDK4 germ-
line mutation: phenotypic profile and associa-
tions with MC1R variants. J Med Genet 50:
264–70
Robles-Espinoza CD, Harland M, Ramsay AJ et al.
(2014) POT1 loss-of-function variants predis-
pose to familial melanoma. Nat Genet
46:478–81
Scolyer RA, Long GV, Thompson JF (2011) Evol-
ving concepts in melanoma classification and
their relevance to multidisciplinary melanoma
patient care. Mol Oncol 5:124–36
Yokoyama S, Woods SL, Boyle GM et al. (2011) A
novel recurrent mutation in MITF predisposes
to familial and sporadic melanoma. Nature
480:99–103
Zebary A, Omholt K, van Doorn R et al. (2014)
Somatic BRAF and NRAS mutations in famil-
ial melanomas with known germline
CDKN2A status: a GenoMEL study. J Invest
Dermatol 134:287–90
Silver Nanoparticle–Induced hMSC Proliferation Is
Associated with HIF-1a-Mediated Upregulation of IL-8
Expression
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TO THE EDITOR
A recent study has reported that the
application of silver nanoparticles
(AgNPs) enhances wound healing (Tian
et al., 2007). Human mesenchymal stem
cells (hMSCs) could enhance normal
and impaired wound healing (Shin and
Peterson, 2013). A previous paper
showed that AgNPs might exert cyto-
toxic effects on hMSCs at high concen-
trations, but also induce cell activation
at subtoxic silver concentrations
(Greulich et al., 2009; Hackenberg
et al., 2011). Nonetheless, the effects
of AgNP-treated hMSCs in wound
healing remain unknown.
Rennekampff et al. (2000) reported
that IL-8 might be a growth factor for
the epithelium. It has been suggested
that AgNPs could contribute to wound
healing by increasing cell proliferation
via upregulation of IL-8 (Hackenberg
et al., 2011). However, there is a lack
of information on the regulatory mech-
anism of IL-8 in AgNP-treated hMSCs.
Hypoxia-inducible factor-1a (HIF-1a)
acts as transcription factor in regulating
metabolism, development, proliferation,
and pathology under hypoxic conditions
(Liu et al., 2013). Yu et al. (2007) also
demonstrated that wound healing in
diabetic patients is associated with an
increase in the synthesis of HIF-1a
protein. In this study, we investigated
the role of HIF-1a in AgNP-mediated
cell proliferation and IL-8 upregulation
in hMSCs.
The present study measured cell pro-
liferation and the expression of HIF-1a
and IL-8 in hMSCs treated with AgNPs.
In addition, this study investigated the
effect of small interfering RNA specific
for HIF-1a (HIF-1a siRNA) on cell pro-
liferation and IL-8 expression in hMSCs.
Polyvinylpyrrolidone-coated spherical
AgNPs (nanoComposix, San Diego,
CA) were used in this study. AgNPs
were characterized by transmission
electron microscopy before performing
the experiment (Figure 1a). The energy
diverse X-ray spectra demonstrated the
strong presence of Ag (Figure 1b). In
accordance with a previous study
(Hackenberg et al., 2011), AgNPs
increased cell proliferation in a dose-
dependent manner at subtoxic concen-
trations and decreased cell proliferation
at higher concentrations above
10mg ml1 (Figure 1c and e). As shown
in Figure 1d and f, a marked increase in
cell proliferation was observed after
treatment with AgNPs. To determine
the effect of AgNPs on IL-8 mRNA
expression, we treated hMSCs with
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